Vanda Pharmaceuticals Inc. (VNDA) 10-Year Financial Performance & Capital Metrics

VNDA • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Show more

Revenue $199M +3.2%
EBITDA -$33M -197.3%
Net Income -$19M -853.3%
EPS (Diluted) -0.32 -833.9%
Gross Margin 94.31% +2.2%
EBITDA Margin -16.36% -188.1%
Operating Margin -20.46% -182.4%
Net Margin -9.51% -830.1%
ROE -3.49% -845.5%
ROIC -7.03% -176.2%
Debt/Equity 0.02 +33.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 91 (top 9%)
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y14.76%

5Y-2.64%

3Y-9.56%

TTM11.12%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-413.78%

EPS CAGR

10Y-

5Y-

3Y-

TTM-404.25%

ROCE

10Y Avg-2.47%

5Y Avg1.21%

3Y Avg-2.87%

Latest-7.28%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.48B	26.46	19.46	31.85%	24.94%	28.47%	3.51%	0.07
JAZZJazz Pharmaceuticals plc	9.87B	162.43	18.78	6.12%	-8.86%	-9.31%	13.66%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.75B	22.35	17.06	23.49%	37.63%	23.64%	8.71%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.06B	35.76	14.25	22.8%	22.48%	22.23%	10.62%	0.28
ALKSAlkermes plc	4.81B	29.15	13.43	-6.36%	22.27%	19.55%	8.43%	0.05
PRTCPureTech Health plc	437.45M	18.10	9.05	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	500.67M	19.79	-1.11
NMRANeumora Therapeutics, Inc. Common Stock	363.67M	2.14	-1.40			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	109.92M	146.02M	165.08M	193.12M	227.19M	248.17M	268.68M	254.38M	192.64M	198.77M
Revenue Growth %	1.19%	0.33%	0.13%	0.17%	0.18%	0.09%	0.08%	-0.05%	-0.24%	0.03%
Cost of Goods Sold+	23.46M	24.71M	17.85M	20.51M	24.49M	23.36M	25.63M	24.28M	14.8M	11.31M
COGS % of Revenue	0.21%	0.17%	0.11%	0.11%	0.11%	0.09%	0.1%	0.1%	0.08%	0.06%
Gross Profit+	86.46M	121.31M	147.24M	172.61M	202.7M	224.8M	243.05M	230.1M	177.84M	187.46M
Gross Margin %	0.79%	0.83%	0.89%	0.89%	0.89%	0.91%	0.9%	0.9%	0.92%	0.94%
Gross Profit Growth %	0.78%	0.4%	0.21%	0.17%	0.17%	0.11%	0.08%	-0.05%	-0.23%	0.05%
Operating Expenses+	126.65M	139.88M	164.14M	150.87M	179.89M	197.56M	200.89M	223.77M	191.8M	228.12M
OpEx % of Revenue	1.15%	0.96%	0.99%	0.78%	0.79%	0.8%	0.75%	0.88%	1%	1.15%
Selling, General & Admin	84.53M	99.79M	123.84M	105.75M	129.74M	140.51M	124.05M	136.49M	112.88M	146.41M
SG&A % of Revenue	0.77%	0.68%	0.75%	0.55%	0.57%	0.57%	0.46%	0.54%	0.59%	0.74%
Research & Development	29.14M	29.16M	38.55M	43.59M	48.65M	55.58M	75.36M	85.77M	76.82M	74.43M
R&D % of Revenue	0.27%	0.2%	0.23%	0.23%	0.21%	0.22%	0.28%	0.34%	0.4%	0.37%
Other Operating Expenses	320K	665K	1.47M	3.61M	1.5M	1.48M	1.48M	1.52M	2.09M	7.27M
Operating Income+	-40.19M	-18.57M	-16.9M	21.74M	22.81M	27.24M	42.16M	6.33M	-13.95M	-40.66M
Operating Margin %	-0.37%	-0.13%	-0.1%	0.11%	0.1%	0.11%	0.16%	0.02%	-0.07%	-0.2%
Operating Income Growth %	-3%	0.54%	0.09%	2.29%	0.05%	0.19%	0.55%	-0.85%	-3.2%	-1.91%
EBITDA+	-27.21M	-6.7M	-13.92M	24.69M	25.7M	30.1M	45.01M	9.06M	-10.94M	-32.53M
EBITDA Margin %	-0.25%	-0.05%	-0.08%	0.13%	0.11%	0.12%	0.17%	0.04%	-0.06%	-0.16%
EBITDA Growth %	-2.22%	0.75%	-1.08%	2.77%	0.04%	0.17%	0.5%	-0.8%	-2.21%	-1.97%
D&A (Non-Cash Add-back)	12.97M	11.87M	2.98M	2.96M	2.89M	2.86M	2.84M	2.73M	3.01M	8.13M
EBIT	-40.19M	-18.57M	-16.9M	21.74M	22.81M	31.66M	42.16M	6.33M	-13.95M	-40.66M
Net Interest Income+	0	0	0	0	6.22M	4.42M	199K	0	0	0
Interest Income	0	0	0	0	6.22M	4.42M	199K	0	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	320K	665K	1.47M	3.61M	6.22M	4.42M	199K	4.97M	20.29M	17.74M
Pretax Income+	-39.87M	-17.91M	-15.43M	25.35M	29.03M	31.66M	42.36M	11.3M	6.34M	-22.92M
Pretax Margin %	-0.36%	-0.12%	-0.09%	0.13%	0.13%	0.13%	0.16%	0.04%	0.03%	-0.12%
Income Tax+	0	104K	136K	138K	-86.53M	8.32M	9.21M	5.03M	3.83M	-4.02M
Effective Tax Rate %	1%	1.01%	1.01%	0.99%	3.98%	0.74%	0.78%	0.56%	0.4%	0.82%
Net Income+	-39.87M	-18.01M	-15.57M	25.21M	115.55M	23.34M	33.15M	6.28M	2.51M	-18.9M
Net Margin %	-0.36%	-0.12%	-0.09%	0.13%	0.51%	0.09%	0.12%	0.02%	0.01%	-0.1%
Net Income Growth %	-2.97%	0.55%	0.14%	2.62%	3.58%	-0.8%	0.42%	-0.81%	-0.6%	-8.53%
Net Income (Continuing)	-39.87M	-18.01M	-15.57M	25.21M	115.55M	23.34M	33.15M	6.28M	2.51M	-18.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.94	-0.41	-0.35	0.48	2.11	0.42	0.58	0.11	0.04	-0.32
EPS Growth %	-2.71%	0.56%	0.15%	2.37%	3.4%	-0.8%	0.38%	-0.81%	-0.6%	-8.34%
EPS (Basic)	-0.94	-0.41	-0.35	0.50	2.17	0.43	0.60	0.11	0.04	-0.32
Diluted Shares Outstanding	42.25M	43.45M	44.74M	53.05M	54.85M	55.19M	56.92M	56.98M	57.56M	58.15M
Basic Shares Outstanding	42.25M	43.45M	44.48M	50.86M	53.14M	54.43M	55.55M	56.46M	57.38M	58.15M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	166.55M	174.18M	169.86M	299.13M	354.14M	409.14M	478.3M	519.29M	432.95M	438.89M
Cash & Short-Term Investments	143.18M	141.34M	143.41M	257.36M	312.13M	367.74M	432.81M	466.86M	388.26M	374.64M
Cash Only	50.84M	40.43M	33.63M	61.01M	45.07M	61.03M	52.07M	135.03M	135.82M	102.32M
Short-Term Investments	92.34M	100.91M	109.79M	196.35M	267.06M	306.71M	380.74M	331.83M	252.44M	272.33M
Accounts Receivable	16.33M	20.27M	17.6M	28.78M	26.37M	30.04M	32.47M	33.51M	34.16M	47.1M
Days Sales Outstanding	54.23	50.66	38.92	54.4	42.36	44.18	44.11	48.08	64.71	86.49
Inventory	1.29M	779K	840K	994K	1.14M	1.28M	1.02M	1.19M	1.36M	1.73M
Days Inventory Outstanding	20.13	11.51	17.18	17.69	16.99	20	14.6	17.95	33.48	55.68
Other Current Assets	5.74M	3.98M	8M	0	14.5M	0	0	17.73M	9.17M	15.42M
Total Non-Current Assets+	46.5M	36.2M	35.57M	33M	129.61M	124.31M	115.49M	114.95M	215.49M	217.31M
Property, Plant & Equipment	4.57M	5.01M	5.31M	4.42M	15.04M	14.6M	12.38M	10.97M	9.14M	12.68M
Fixed Asset Turnover	24.05x	29.12x	31.11x	43.72x	15.10x	17.00x	21.69x	23.18x	21.08x	15.68x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	38.75M	27.82M	26.07M	24.54M	23.04M	21.56M	20.08M	18.57M	121.37M	114.1M
Long-Term Investments	0	800K	0	600K	578K	0	0	0	0	0
Other Non-Current Assets	3.18M	2.46M	4.19M	4.04M	3.27M	6.64M	8.15M	11.38M	9.98M	9.1M
Total Assets+	213.05M	210.37M	205.43M	332.13M	483.75M	533.46M	593.79M	634.25M	648.44M	656.2M
Asset Turnover	0.52x	0.69x	0.80x	0.58x	0.47x	0.47x	0.45x	0.40x	0.30x	0.30x
Asset Growth %	0.24%	-0.01%	-0.02%	0.62%	0.46%	0.1%	0.11%	0.07%	0.02%	0.01%
Total Current Liabilities+	51.32M	50.32M	70.36M	53.02M	59.51M	65.94M	74.42M	91.44M	87.7M	99.98M
Accounts Payable	0	0	0	0	5.9M	1.05M	925K	12.69M	7.14M	3.5M
Days Payables Outstanding	-	-	-	-	88	16.39	13.17	190.75	176.26	112.85
Short-Term Debt	0	0	0	0	2.15M	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	-3.42M	50.03M	41.48M	44.86M	45.38M	27.68M	34.01M	69.33M	69.36M
Current Ratio	3.25x	3.46x	2.41x	5.64x	5.95x	6.21x	6.43x	5.68x	4.94x	4.39x
Quick Ratio	3.22x	3.45x	2.40x	5.62x	5.93x	6.19x	6.41x	5.67x	4.92x	4.37x
Cash Conversion Cycle	-	-	-	-	-28.65	47.78	45.53	-124.72	-78.07	29.32
Total Non-Current Liabilities+	28.71M	28.72M	3.67M	3.69M	13.3M	14.25M	14.45M	15.61M	15.83M	17.68M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	12.46M	11.5M	10.05M	8.81M	7.01M	8.09M
Deferred Tax Liabilities	0	0	100K	100K	0	0	0	0	0	0
Other Non-Current Liabilities	28.71M	28.72M	3.67M	3.69M	843K	2.76M	4.39M	6.8M	8.83M	9.59M
Total Liabilities	80.02M	79.04M	74.04M	56.71M	72.8M	80.19M	88.86M	107.05M	103.53M	117.66M
Total Debt+	0	0	0	0	14.6M	13.61M	12.37M	11.14M	9.4M	12.36M
Net Debt	-50.84M	-40.43M	-33.63M	-61.01M	-30.47M	-47.42M	-39.7M	-123.89M	-126.42M	-89.96M
Debt / Equity	-	-	-	-	0.04x	0.03x	0.02x	0.02x	0.02x	0.02x
Debt / EBITDA	-	-	-	-	0.57x	0.45x	0.27x	1.23x	-	-
Net Debt / EBITDA	-	-	-	-2.47x	-1.19x	-1.58x	-0.88x	-13.67x	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	133.03M	131.33M	131.39M	275.42M	410.94M	453.27M	504.93M	527.2M	544.91M	538.55M
Equity Growth %	-0.17%	-0.01%	0%	1.1%	0.49%	0.1%	0.11%	0.04%	0.03%	-0.01%
Book Value per Share	3.15	3.02	2.94	5.19	7.49	8.21	8.87	9.25	9.47	9.26
Total Shareholders' Equity	133.03M	131.33M	131.39M	275.42M	410.94M	453.27M	504.93M	527.2M	544.91M	538.55M
Common Stock	43K	44K	45K	52K	54K	55K	56K	57K	58K	58K
Retained Earnings	-327.85M	-345.86M	-361.43M	-336.22M	-220.66M	-197.33M	-164.18M	-157.9M	-155.39M	-174.29M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	39K	58K	-34K	1K	249K	239K	-175K	-1.19M	-30K	74K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	12.45M	-8.1M	-1.98M	29.99M	45.95M	51.77M	64.21M	31.98M	12.8M	-15.76M
Operating CF Margin %	0.11%	-0.06%	-0.01%	0.16%	0.2%	0.21%	0.24%	0.13%	0.07%	-0.08%
Operating CF Growth %	1.15%	-1.65%	0.76%	16.12%	0.53%	0.13%	0.24%	-0.5%	-0.6%	-2.23%
Net Income	-39.87M	-18.01M	-15.57M	25.21M	115.55M	23.34M	33.15M	6.28M	2.51M	-18.9M
Depreciation & Amortization	13.55M	11.87M	2.98M	2.96M	2.89M	2.86M	2.84M	2.73M	3.01M	8.13M
Stock-Based Compensation	7.96M	8.54M	10.46M	11.67M	0	0	0	0	14.04M	12.43M
Deferred Taxes	677K	-104K	-426K	-2.22M	-87.77M	6.19M	6.75M	1.13M	-1.29M	-6.48M
Other Non-Cash Items	657K	708K	587K	167K	12.14M	15.07M	18.74M	15.77M	-4.72M	-4.38M
Working Capital Changes	29.46M	-11.11M	-26K	-7.79M	3.13M	4.32M	2.74M	6.07M	-747K	-6.56M
Change in Receivables	-12.68M	-4.3M	2.52M	-11.21M	2.34M	-3.77M	-2.47M	-1.09M	-707K	-13.01M
Change in Inventory	387K	200K	-1.06M	70K	-722K	-2.88M	-2.23M	-4.48M	-771K	-29K
Change in Payables	9.43M	575K	5.95M	-4.88M	3.51M	3.76M	3.04M	11.79M	-10.98M	1.71M
Cash from Investing+	-26.6M	-10.07M	-10.11M	-109.66M	-68.31M	-41.5M	-76.7M	49.92M	-12.06M	-17.43M
Capital Expenditures	-2.53M	-1.41M	-1.66M	-25.37M	-1.02M	-1.79M	-552K	-679K	-383K	-490K
CapEx % of Revenue	0.02%	0.01%	0.01%	0.13%	0%	0.01%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-24.07M	-46K	124K	-25M	0	0	0	0	0	0
Cash from Financing+	4.09M	7.75M	5.25M	107.13M	6.26M	5.63M	3.55M	734K	0	-155K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.09M	7.75M	5.25M	6.26M	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	9.92M	-9.51M	-3.65M	4.62M	44.93M	49.98M	63.66M	31.3M	12.42M	-16.25M
FCF Margin %	0.09%	-0.07%	-0.02%	0.02%	0.2%	0.2%	0.24%	0.12%	0.06%	-0.08%
FCF Growth %	1.11%	-1.96%	0.62%	2.27%	8.73%	0.11%	0.27%	-0.51%	-0.6%	-2.31%
FCF per Share	0.23	-0.22	-0.08	0.09	0.82	0.91	1.12	0.55	0.22	-0.28
FCF Conversion (FCF/Net Income)	-0.31x	0.45x	0.13x	1.19x	0.40x	2.22x	1.94x	5.10x	5.10x	0.83x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-27.13%	-13.63%	-11.85%	12.39%	33.67%	5.4%	6.92%	1.22%	0.47%	-3.49%
Return on Invested Capital (ROIC)	-33.1%	-16.09%	-13.44%	10.45%	5.75%	5.2%	7.26%	1.09%	-2.55%	-7.03%
Gross Margin	78.66%	83.08%	89.19%	89.38%	89.22%	90.59%	90.46%	90.45%	92.32%	94.31%
Net Margin	-36.27%	-12.33%	-9.43%	13.05%	50.86%	9.4%	12.34%	2.47%	1.3%	-9.51%
Debt / Equity	-	-	-	-	0.04x	0.03x	0.02x	0.02x	0.02x	0.02x
FCF Conversion	-0.31x	0.45x	0.13x	1.19x	0.40x	2.22x	1.94x	5.10x	5.10x	0.83x
Revenue Growth	119.16%	32.83%	13.06%	16.98%	17.64%	9.23%	8.27%	-5.32%	-24.27%	3.18%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Fanapt	65.62M	74.35M	75.11M	77.28M	84.21M	87.48M	95.15M	94.73M	90.87M	94.3M
Fanapt Growth	-	13.29%	1.02%	2.90%	8.96%	3.89%	8.76%	-0.44%	-4.07%	3.77%
Hetlioz	44.3M	71.67M	89.98M	115.83M	142.98M	160.69M	173.54M	159.66M	100.17M	76.67M
Hetlioz Growth	-	61.78%	25.54%	28.74%	23.43%	12.38%	8.00%	-8.00%	-37.26%	-23.45%

Frequently Asked Questions

Growth & Financials

Vanda Pharmaceuticals Inc. (VNDA) reported $212.1M in revenue for fiscal year 2024. This represents a 578% increase from $31.3M in 2011.

Vanda Pharmaceuticals Inc. (VNDA) grew revenue by 3.2% over the past year. Growth has been modest.

Vanda Pharmaceuticals Inc. (VNDA) reported a net loss of $84.2M for fiscal year 2024.

Dividend & Returns

Vanda Pharmaceuticals Inc. (VNDA) has a return on equity (ROE) of -3.5%. Negative ROE indicates the company is unprofitable.

Vanda Pharmaceuticals Inc. (VNDA) had negative free cash flow of $83.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Vanda Pharmaceuticals Inc. (VNDA) 10-Year Financial Performance & Capital Metrics

VNDA • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $199M +3.2%
EBITDA -$33M -197.3%
Net Income -$19M -853.3%
EPS (Diluted) -0.32 -833.9%
Gross Margin 94.31% +2.2%
EBITDA Margin -16.36% -188.1%
Operating Margin -20.46% -182.4%
Net Margin -9.51% -830.1%
ROE -3.49% -845.5%
ROIC -7.03% -176.2%
Debt/Equity 0.02 +33.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 91 (top 9%)
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y14.76%

5Y-2.64%

3Y-9.56%

TTM11.12%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-413.78%

EPS CAGR

10Y-

5Y-

3Y-

TTM-404.25%

ROCE

10Y Avg-2.47%

5Y Avg1.21%

3Y Avg-2.87%

Latest-7.28%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.48B	26.46	19.46	31.85%	24.94%	28.47%	3.51%	0.07
JAZZJazz Pharmaceuticals plc	9.87B	162.43	18.78	6.12%	-8.86%	-9.31%	13.66%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.75B	22.35	17.06	23.49%	37.63%	23.64%	8.71%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.06B	35.76	14.25	22.8%	22.48%	22.23%	10.62%	0.28
ALKSAlkermes plc	4.81B	29.15	13.43	-6.36%	22.27%	19.55%	8.43%	0.05
PRTCPureTech Health plc	437.45M	18.10	9.05	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	500.67M	19.79	-1.11
NMRANeumora Therapeutics, Inc. Common Stock	363.67M	2.14	-1.40			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	109.92M	146.02M	165.08M	193.12M	227.19M	248.17M	268.68M	254.38M	192.64M	198.77M
Revenue Growth %	1.19%	0.33%	0.13%	0.17%	0.18%	0.09%	0.08%	-0.05%	-0.24%	0.03%
Cost of Goods Sold+	23.46M	24.71M	17.85M	20.51M	24.49M	23.36M	25.63M	24.28M	14.8M	11.31M
COGS % of Revenue	0.21%	0.17%	0.11%	0.11%	0.11%	0.09%	0.1%	0.1%	0.08%	0.06%
Gross Profit+	86.46M	121.31M	147.24M	172.61M	202.7M	224.8M	243.05M	230.1M	177.84M	187.46M
Gross Margin %	0.79%	0.83%	0.89%	0.89%	0.89%	0.91%	0.9%	0.9%	0.92%	0.94%
Gross Profit Growth %	0.78%	0.4%	0.21%	0.17%	0.17%	0.11%	0.08%	-0.05%	-0.23%	0.05%
Operating Expenses+	126.65M	139.88M	164.14M	150.87M	179.89M	197.56M	200.89M	223.77M	191.8M	228.12M
OpEx % of Revenue	1.15%	0.96%	0.99%	0.78%	0.79%	0.8%	0.75%	0.88%	1%	1.15%
Selling, General & Admin	84.53M	99.79M	123.84M	105.75M	129.74M	140.51M	124.05M	136.49M	112.88M	146.41M
SG&A % of Revenue	0.77%	0.68%	0.75%	0.55%	0.57%	0.57%	0.46%	0.54%	0.59%	0.74%
Research & Development	29.14M	29.16M	38.55M	43.59M	48.65M	55.58M	75.36M	85.77M	76.82M	74.43M
R&D % of Revenue	0.27%	0.2%	0.23%	0.23%	0.21%	0.22%	0.28%	0.34%	0.4%	0.37%
Other Operating Expenses	320K	665K	1.47M	3.61M	1.5M	1.48M	1.48M	1.52M	2.09M	7.27M
Operating Income+	-40.19M	-18.57M	-16.9M	21.74M	22.81M	27.24M	42.16M	6.33M	-13.95M	-40.66M
Operating Margin %	-0.37%	-0.13%	-0.1%	0.11%	0.1%	0.11%	0.16%	0.02%	-0.07%	-0.2%
Operating Income Growth %	-3%	0.54%	0.09%	2.29%	0.05%	0.19%	0.55%	-0.85%	-3.2%	-1.91%
EBITDA+	-27.21M	-6.7M	-13.92M	24.69M	25.7M	30.1M	45.01M	9.06M	-10.94M	-32.53M
EBITDA Margin %	-0.25%	-0.05%	-0.08%	0.13%	0.11%	0.12%	0.17%	0.04%	-0.06%	-0.16%
EBITDA Growth %	-2.22%	0.75%	-1.08%	2.77%	0.04%	0.17%	0.5%	-0.8%	-2.21%	-1.97%
D&A (Non-Cash Add-back)	12.97M	11.87M	2.98M	2.96M	2.89M	2.86M	2.84M	2.73M	3.01M	8.13M
EBIT	-40.19M	-18.57M	-16.9M	21.74M	22.81M	31.66M	42.16M	6.33M	-13.95M	-40.66M
Net Interest Income+	0	0	0	0	6.22M	4.42M	199K	0	0	0
Interest Income	0	0	0	0	6.22M	4.42M	199K	0	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	320K	665K	1.47M	3.61M	6.22M	4.42M	199K	4.97M	20.29M	17.74M
Pretax Income+	-39.87M	-17.91M	-15.43M	25.35M	29.03M	31.66M	42.36M	11.3M	6.34M	-22.92M
Pretax Margin %	-0.36%	-0.12%	-0.09%	0.13%	0.13%	0.13%	0.16%	0.04%	0.03%	-0.12%
Income Tax+	0	104K	136K	138K	-86.53M	8.32M	9.21M	5.03M	3.83M	-4.02M
Effective Tax Rate %	1%	1.01%	1.01%	0.99%	3.98%	0.74%	0.78%	0.56%	0.4%	0.82%
Net Income+	-39.87M	-18.01M	-15.57M	25.21M	115.55M	23.34M	33.15M	6.28M	2.51M	-18.9M
Net Margin %	-0.36%	-0.12%	-0.09%	0.13%	0.51%	0.09%	0.12%	0.02%	0.01%	-0.1%
Net Income Growth %	-2.97%	0.55%	0.14%	2.62%	3.58%	-0.8%	0.42%	-0.81%	-0.6%	-8.53%
Net Income (Continuing)	-39.87M	-18.01M	-15.57M	25.21M	115.55M	23.34M	33.15M	6.28M	2.51M	-18.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.94	-0.41	-0.35	0.48	2.11	0.42	0.58	0.11	0.04	-0.32
EPS Growth %	-2.71%	0.56%	0.15%	2.37%	3.4%	-0.8%	0.38%	-0.81%	-0.6%	-8.34%
EPS (Basic)	-0.94	-0.41	-0.35	0.50	2.17	0.43	0.60	0.11	0.04	-0.32
Diluted Shares Outstanding	42.25M	43.45M	44.74M	53.05M	54.85M	55.19M	56.92M	56.98M	57.56M	58.15M
Basic Shares Outstanding	42.25M	43.45M	44.48M	50.86M	53.14M	54.43M	55.55M	56.46M	57.38M	58.15M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	166.55M	174.18M	169.86M	299.13M	354.14M	409.14M	478.3M	519.29M	432.95M	438.89M
Cash & Short-Term Investments	143.18M	141.34M	143.41M	257.36M	312.13M	367.74M	432.81M	466.86M	388.26M	374.64M
Cash Only	50.84M	40.43M	33.63M	61.01M	45.07M	61.03M	52.07M	135.03M	135.82M	102.32M
Short-Term Investments	92.34M	100.91M	109.79M	196.35M	267.06M	306.71M	380.74M	331.83M	252.44M	272.33M
Accounts Receivable	16.33M	20.27M	17.6M	28.78M	26.37M	30.04M	32.47M	33.51M	34.16M	47.1M
Days Sales Outstanding	54.23	50.66	38.92	54.4	42.36	44.18	44.11	48.08	64.71	86.49
Inventory	1.29M	779K	840K	994K	1.14M	1.28M	1.02M	1.19M	1.36M	1.73M
Days Inventory Outstanding	20.13	11.51	17.18	17.69	16.99	20	14.6	17.95	33.48	55.68
Other Current Assets	5.74M	3.98M	8M	0	14.5M	0	0	17.73M	9.17M	15.42M
Total Non-Current Assets+	46.5M	36.2M	35.57M	33M	129.61M	124.31M	115.49M	114.95M	215.49M	217.31M
Property, Plant & Equipment	4.57M	5.01M	5.31M	4.42M	15.04M	14.6M	12.38M	10.97M	9.14M	12.68M
Fixed Asset Turnover	24.05x	29.12x	31.11x	43.72x	15.10x	17.00x	21.69x	23.18x	21.08x	15.68x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	38.75M	27.82M	26.07M	24.54M	23.04M	21.56M	20.08M	18.57M	121.37M	114.1M
Long-Term Investments	0	800K	0	600K	578K	0	0	0	0	0
Other Non-Current Assets	3.18M	2.46M	4.19M	4.04M	3.27M	6.64M	8.15M	11.38M	9.98M	9.1M
Total Assets+	213.05M	210.37M	205.43M	332.13M	483.75M	533.46M	593.79M	634.25M	648.44M	656.2M
Asset Turnover	0.52x	0.69x	0.80x	0.58x	0.47x	0.47x	0.45x	0.40x	0.30x	0.30x
Asset Growth %	0.24%	-0.01%	-0.02%	0.62%	0.46%	0.1%	0.11%	0.07%	0.02%	0.01%
Total Current Liabilities+	51.32M	50.32M	70.36M	53.02M	59.51M	65.94M	74.42M	91.44M	87.7M	99.98M
Accounts Payable	0	0	0	0	5.9M	1.05M	925K	12.69M	7.14M	3.5M
Days Payables Outstanding	-	-	-	-	88	16.39	13.17	190.75	176.26	112.85
Short-Term Debt	0	0	0	0	2.15M	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	-3.42M	50.03M	41.48M	44.86M	45.38M	27.68M	34.01M	69.33M	69.36M
Current Ratio	3.25x	3.46x	2.41x	5.64x	5.95x	6.21x	6.43x	5.68x	4.94x	4.39x
Quick Ratio	3.22x	3.45x	2.40x	5.62x	5.93x	6.19x	6.41x	5.67x	4.92x	4.37x
Cash Conversion Cycle	-	-	-	-	-28.65	47.78	45.53	-124.72	-78.07	29.32
Total Non-Current Liabilities+	28.71M	28.72M	3.67M	3.69M	13.3M	14.25M	14.45M	15.61M	15.83M	17.68M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	12.46M	11.5M	10.05M	8.81M	7.01M	8.09M
Deferred Tax Liabilities	0	0	100K	100K	0	0	0	0	0	0
Other Non-Current Liabilities	28.71M	28.72M	3.67M	3.69M	843K	2.76M	4.39M	6.8M	8.83M	9.59M
Total Liabilities	80.02M	79.04M	74.04M	56.71M	72.8M	80.19M	88.86M	107.05M	103.53M	117.66M
Total Debt+	0	0	0	0	14.6M	13.61M	12.37M	11.14M	9.4M	12.36M
Net Debt	-50.84M	-40.43M	-33.63M	-61.01M	-30.47M	-47.42M	-39.7M	-123.89M	-126.42M	-89.96M
Debt / Equity	-	-	-	-	0.04x	0.03x	0.02x	0.02x	0.02x	0.02x
Debt / EBITDA	-	-	-	-	0.57x	0.45x	0.27x	1.23x	-	-
Net Debt / EBITDA	-	-	-	-2.47x	-1.19x	-1.58x	-0.88x	-13.67x	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	133.03M	131.33M	131.39M	275.42M	410.94M	453.27M	504.93M	527.2M	544.91M	538.55M
Equity Growth %	-0.17%	-0.01%	0%	1.1%	0.49%	0.1%	0.11%	0.04%	0.03%	-0.01%
Book Value per Share	3.15	3.02	2.94	5.19	7.49	8.21	8.87	9.25	9.47	9.26
Total Shareholders' Equity	133.03M	131.33M	131.39M	275.42M	410.94M	453.27M	504.93M	527.2M	544.91M	538.55M
Common Stock	43K	44K	45K	52K	54K	55K	56K	57K	58K	58K
Retained Earnings	-327.85M	-345.86M	-361.43M	-336.22M	-220.66M	-197.33M	-164.18M	-157.9M	-155.39M	-174.29M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	39K	58K	-34K	1K	249K	239K	-175K	-1.19M	-30K	74K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	12.45M	-8.1M	-1.98M	29.99M	45.95M	51.77M	64.21M	31.98M	12.8M	-15.76M
Operating CF Margin %	0.11%	-0.06%	-0.01%	0.16%	0.2%	0.21%	0.24%	0.13%	0.07%	-0.08%
Operating CF Growth %	1.15%	-1.65%	0.76%	16.12%	0.53%	0.13%	0.24%	-0.5%	-0.6%	-2.23%
Net Income	-39.87M	-18.01M	-15.57M	25.21M	115.55M	23.34M	33.15M	6.28M	2.51M	-18.9M
Depreciation & Amortization	13.55M	11.87M	2.98M	2.96M	2.89M	2.86M	2.84M	2.73M	3.01M	8.13M
Stock-Based Compensation	7.96M	8.54M	10.46M	11.67M	0	0	0	0	14.04M	12.43M
Deferred Taxes	677K	-104K	-426K	-2.22M	-87.77M	6.19M	6.75M	1.13M	-1.29M	-6.48M
Other Non-Cash Items	657K	708K	587K	167K	12.14M	15.07M	18.74M	15.77M	-4.72M	-4.38M
Working Capital Changes	29.46M	-11.11M	-26K	-7.79M	3.13M	4.32M	2.74M	6.07M	-747K	-6.56M
Change in Receivables	-12.68M	-4.3M	2.52M	-11.21M	2.34M	-3.77M	-2.47M	-1.09M	-707K	-13.01M
Change in Inventory	387K	200K	-1.06M	70K	-722K	-2.88M	-2.23M	-4.48M	-771K	-29K
Change in Payables	9.43M	575K	5.95M	-4.88M	3.51M	3.76M	3.04M	11.79M	-10.98M	1.71M
Cash from Investing+	-26.6M	-10.07M	-10.11M	-109.66M	-68.31M	-41.5M	-76.7M	49.92M	-12.06M	-17.43M
Capital Expenditures	-2.53M	-1.41M	-1.66M	-25.37M	-1.02M	-1.79M	-552K	-679K	-383K	-490K
CapEx % of Revenue	0.02%	0.01%	0.01%	0.13%	0%	0.01%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-24.07M	-46K	124K	-25M	0	0	0	0	0	0
Cash from Financing+	4.09M	7.75M	5.25M	107.13M	6.26M	5.63M	3.55M	734K	0	-155K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.09M	7.75M	5.25M	6.26M	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	9.92M	-9.51M	-3.65M	4.62M	44.93M	49.98M	63.66M	31.3M	12.42M	-16.25M
FCF Margin %	0.09%	-0.07%	-0.02%	0.02%	0.2%	0.2%	0.24%	0.12%	0.06%	-0.08%
FCF Growth %	1.11%	-1.96%	0.62%	2.27%	8.73%	0.11%	0.27%	-0.51%	-0.6%	-2.31%
FCF per Share	0.23	-0.22	-0.08	0.09	0.82	0.91	1.12	0.55	0.22	-0.28
FCF Conversion (FCF/Net Income)	-0.31x	0.45x	0.13x	1.19x	0.40x	2.22x	1.94x	5.10x	5.10x	0.83x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-27.13%	-13.63%	-11.85%	12.39%	33.67%	5.4%	6.92%	1.22%	0.47%	-3.49%
Return on Invested Capital (ROIC)	-33.1%	-16.09%	-13.44%	10.45%	5.75%	5.2%	7.26%	1.09%	-2.55%	-7.03%
Gross Margin	78.66%	83.08%	89.19%	89.38%	89.22%	90.59%	90.46%	90.45%	92.32%	94.31%
Net Margin	-36.27%	-12.33%	-9.43%	13.05%	50.86%	9.4%	12.34%	2.47%	1.3%	-9.51%
Debt / Equity	-	-	-	-	0.04x	0.03x	0.02x	0.02x	0.02x	0.02x
FCF Conversion	-0.31x	0.45x	0.13x	1.19x	0.40x	2.22x	1.94x	5.10x	5.10x	0.83x
Revenue Growth	119.16%	32.83%	13.06%	16.98%	17.64%	9.23%	8.27%	-5.32%	-24.27%	3.18%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Fanapt	65.62M	74.35M	75.11M	77.28M	84.21M	87.48M	95.15M	94.73M	90.87M	94.3M
Fanapt Growth	-	13.29%	1.02%	2.90%	8.96%	3.89%	8.76%	-0.44%	-4.07%	3.77%
Hetlioz	44.3M	71.67M	89.98M	115.83M	142.98M	160.69M	173.54M	159.66M	100.17M	76.67M
Hetlioz Growth	-	61.78%	25.54%	28.74%	23.43%	12.38%	8.00%	-8.00%	-37.26%	-23.45%

Frequently Asked Questions

Growth & Financials

Vanda Pharmaceuticals Inc. (VNDA) reported $212.1M in revenue for fiscal year 2024. This represents a 578% increase from $31.3M in 2011.

Vanda Pharmaceuticals Inc. (VNDA) grew revenue by 3.2% over the past year. Growth has been modest.

Vanda Pharmaceuticals Inc. (VNDA) reported a net loss of $84.2M for fiscal year 2024.

Dividend & Returns

Vanda Pharmaceuticals Inc. (VNDA) has a return on equity (ROE) of -3.5%. Negative ROE indicates the company is unprofitable.

Vanda Pharmaceuticals Inc. (VNDA) had negative free cash flow of $83.0M in fiscal year 2024, likely due to heavy capital investments.